Vanguard Group Inc. increased its stake in Pulse Biosciences, Inc. (NASDAQ:PLSE - Free Report) by 15.1% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,146,339 shares of the company's stock after purchasing an additional 150,506 shares during the period. Vanguard Group Inc. owned 1.86% of Pulse Biosciences worth $19,958,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors also recently bought and sold shares of the stock. State Street Corp lifted its stake in shares of Pulse Biosciences by 17.8% during the third quarter. State Street Corp now owns 461,333 shares of the company's stock worth $8,092,000 after buying an additional 69,696 shares during the period. Geode Capital Management LLC raised its stake in Pulse Biosciences by 7.8% in the 3rd quarter. Geode Capital Management LLC now owns 457,165 shares of the company's stock worth $8,020,000 after acquiring an additional 33,200 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in Pulse Biosciences by 0.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 149,206 shares of the company's stock worth $2,598,000 after acquiring an additional 1,092 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in Pulse Biosciences during the 3rd quarter worth about $588,000. Finally, Barclays PLC grew its stake in Pulse Biosciences by 361.4% during the 3rd quarter. Barclays PLC now owns 30,306 shares of the company's stock valued at $530,000 after purchasing an additional 23,738 shares during the last quarter. Hedge funds and other institutional investors own 76.95% of the company's stock.
Pulse Biosciences Stock Performance
NASDAQ PLSE traded up $0.98 on Tuesday, hitting $18.27. 160,583 shares of the company's stock traded hands, compared to its average volume of 197,355. The firm's 50-day moving average price is $17.17 and its two-hundred day moving average price is $17.96. Pulse Biosciences, Inc. has a 1-year low of $6.60 and a 1-year high of $25.00.
Analyst Ratings Changes
Separately, StockNews.com raised Pulse Biosciences to a "sell" rating in a report on Monday, March 31st.
Read Our Latest Report on Pulse Biosciences
About Pulse Biosciences
(
Free Report)
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Featured Articles
Before you consider Pulse Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.
While Pulse Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
